BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Gamma Delta T cells prove an exciting platform for the treatme
 nt of solid tumor indications and autoimmune disorders. The unique biolog
 y of these cells is revolutionizing the development of allogeneic therapi
 es.\n\nThe 5th rendition of the Gamma Delta T Cell Therapies Summit retur
 ns this year to take a deep dive into the biological intricacies of gamma
  delta T cells\, deciphering the rich landscape of targeted interventions
  and engineering\, and exploit their unique pathways and mechanisms to cr
 eate more effective therapeutics. This is a great opportunity to help the
  community upskill their cross-functional team across discovery\, transla
 tion and clinical development skills\, to successfully translate basic re
 search into your clinical strategy to support upcoming IND submissions.\n
 \nWith a primary focus on streamlining clinical trial design for improved
  targeting of the TME\, exploration of novel engineering strategies and a
 ppeasing regulatory bodies\, we have collaborated with IN8Bio\, Adicet Bi
 o\, Acepodia\, Takeda\, Luminary Therapeutics\, LAVA Therapeutics\, OneCh
 ain Therapeutics and many more expert companies to uncover the translatio
 nal lessons learned in therapies focused on leveraging the inherent biolo
 gical capabilities of gamma delta T cells.\n\nAs the ONLY industry gamma 
 delta T cell-specific meeting running this year\, these three days will e
 xpedite the translation of your vd1/vd2 pipelines from bench to bedside\,
  fostering prompt progress in the field.\n\nURLs:Tickets: https://go.evvn
 t.com/2351166-2?pid=185Brochure: https://go.evvnt.com/2351166-3?pid=185\n
 \nTime: 9:00 AM - 5:00 PM\n\nSpeakers: Alan Guerrero\, Vice President - R
 esearch and Development\, Kiromic\, LLC\, Antara Banerjee\, Senior Direct
 or and Head of Cell Engager Therapies\, Oncology Drug Discovery Unit\, Ta
 keda Pharmaceutical Co. Ltd.\, Beau Webber\, Chief Scientific Officer and
  Founder\, Luminary Therapeutics\, Bryan Kobel\, Chief Executive Officer\
 , TCBiopharm\, Cathriona Foley\, Assistant Professor\, University College
  Cork\, Charles Morris\, Chief Medical Officer\, Lava Therapeutics\, Chri
 s Holland\, Executive Director and Head Of Biometrics\, Immunocore Ltd\, 
 David Taggart\, Senior Scientist - Product Development\, TCBiopharm\, Ed 
 Zhang\, CEO\, Overland Pharmaceuticals\, Ekatherina Goryachikov\, Head of
  Clinical Operations\, Adicet Bio \, Francesco Galimi\, Chief Medical Off
 icer\, Adicet Bio\, Frank Borriello\, Founder and Chief Executive Officer
 \, Alloplex Biotherapeutics\, Haiyan Jiang\, Founder\, President and Chie
 f Scientific Officer\, PointLoma biosciences\, Jeff Liter\, Founder and C
 EO\, Luminary Therapeutics\, Jonathan Fisher\, Principal Investigator\, U
 niversity College London\, Jose Ramon\, Conejo-Garcia Chief Scientific Of
 ficer\, Celleplus Therapeutics\, Jyothi Sethuraman\, Director\, MSAT\, Ad
 icet Bio\, Laura Garcia Perez\, Senior Scientist\, OneChain Immunotherape
 utics\, Lawrence Lamb\, Chief Scientific Officer and Executive Vice Presi
 dent\, IN8Bio\, Marta Barisa\, Senior Manager - Scientific Project and Re
 search Fellow\, University College London\, Meisam Naeimi\, Kararoudi Dir
 ector - Gene editing Core and Principal Investigator - Childhood Cancer a
 nd Blood Disorder\, Nationwide Children's Hospital\, Michael Lotze\, Prof
 essor of Surgery\, Immunology and Bioengineering\, UPMC Hillman Cancer Ce
 nter\, Mohammed Alnaggar\, Associate Professor\, Hubei University\, Nandh
 u Sobhana\, Head of Cell Therapy Innovation\, Takeda Pharmaceutical Co. L
 td.\, Nelli Bejanyan\, Associate Professor\, Moffitt Cancer Center\, Paya
 m Zarin\, Associate Director and Research Lead\, GentiBio\, Sai-Wen\, Tan
 g Director of Research and Development\, Acepodia Inc.\, Stefanos Theohar
 is\, Chief Executive Officer\, OneChain Immunotherapeutics\, Trishna Gosw
 ami\, Chief Medical Officer\, IN8Bio\, Weiwei Ma\, Chief Technology Offic
 er\, Unicet Biotech\, Xiaohong Wang\, Director\, PointLoma biosciences\n
DTEND:20240731T170000
DTSTAMP:20260512T230903Z
DTSTART:20240729T090000
LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse
 tts\, 02115\,
SEQUENCE:0
SUMMARY:Gamma Delta T cells prove an exciting platform for the treatment o
 f solid tumor indications and autoimmune disorders. The unique biology of
  these c...
UID:c19a1c01-7c1a-418a-bb78-7cfa5d06717f
END:VEVENT
END:VCALENDAR